Trial Profile

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 22 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Odevixibat (Primary)
Indications Intrahepatic cholestasis
Focus Registrational; Therapeutic Use
Acronyms PEDFIC 2
Sponsors Albireo AB; Albireo Pharma

Most Recent Events

10 Jul 2025 Planned End Date changed from 31 Mar 2025 to 15 Aug 2025.
18 Nov 2024 According to Ipsen media release, efficacy and safety data from this study will be presented at the American Association for the Study of Liver Diseases (AASLD).
18 Nov 2024 Results presented in the Ipsen Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com